CA3190081A1 - (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases - Google Patents
(1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseasesInfo
- Publication number
- CA3190081A1 CA3190081A1 CA3190081A CA3190081A CA3190081A1 CA 3190081 A1 CA3190081 A1 CA 3190081A1 CA 3190081 A CA3190081 A CA 3190081A CA 3190081 A CA3190081 A CA 3190081A CA 3190081 A1 CA3190081 A1 CA 3190081A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- treatment
- asthma
- use according
- eosinophils
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382764.7 | 2020-08-21 | ||
| EP20382764.7A EP3957308A1 (en) | 2020-08-21 | 2020-08-21 | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
| PCT/EP2021/073133 WO2022038261A1 (en) | 2020-08-21 | 2021-08-20 | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3190081A1 true CA3190081A1 (en) | 2022-02-24 |
Family
ID=72234795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3190081A Pending CA3190081A1 (en) | 2020-08-21 | 2021-08-20 | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230321053A1 (https=) |
| EP (2) | EP3957308A1 (https=) |
| JP (1) | JP7794807B2 (https=) |
| KR (1) | KR20230054444A (https=) |
| CN (1) | CN115942933A (https=) |
| AU (1) | AU2021327728A1 (https=) |
| BR (1) | BR112023002778A2 (https=) |
| CA (1) | CA3190081A1 (https=) |
| DK (1) | DK4199922T3 (https=) |
| ES (1) | ES3001104T3 (https=) |
| FI (1) | FI4199922T3 (https=) |
| HR (1) | HRP20241621T1 (https=) |
| HU (1) | HUE069338T2 (https=) |
| LT (1) | LT4199922T (https=) |
| MX (1) | MX2023002156A (https=) |
| PL (1) | PL4199922T3 (https=) |
| PT (1) | PT4199922T (https=) |
| RS (1) | RS66263B1 (https=) |
| SI (1) | SI4199922T1 (https=) |
| WO (1) | WO2022038261A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070219223A1 (en) | 2006-03-07 | 2007-09-20 | Endacea, Inc. | Compositions and methods for treating respiratory disorders |
| ES2331220B1 (es) | 2007-10-02 | 2010-09-23 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
| KR20160061352A (ko) | 2013-10-15 | 2016-05-31 | 메디뮨 엘엘씨 | 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법 |
| UA122670C2 (uk) * | 2014-09-08 | 2020-12-28 | Сефалон, Інк. | Спосіб лікування еозинофільної астми у пацієнта |
| ES2676535B1 (es) * | 2017-01-20 | 2019-04-29 | Palobiofarma Sl | Moduladores de los receptores a3 de adenosina |
| LT3592734T (lt) | 2017-03-06 | 2021-07-26 | Palobiofarma, S.L. | (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska |
-
2020
- 2020-08-21 EP EP20382764.7A patent/EP3957308A1/en not_active Withdrawn
-
2021
- 2021-08-20 RS RS20241285A patent/RS66263B1/sr unknown
- 2021-08-20 CA CA3190081A patent/CA3190081A1/en active Pending
- 2021-08-20 MX MX2023002156A patent/MX2023002156A/es unknown
- 2021-08-20 PL PL21765908.5T patent/PL4199922T3/pl unknown
- 2021-08-20 HU HUE21765908A patent/HUE069338T2/hu unknown
- 2021-08-20 FI FIEP21765908.5T patent/FI4199922T3/fi active
- 2021-08-20 DK DK21765908.5T patent/DK4199922T3/da active
- 2021-08-20 AU AU2021327728A patent/AU2021327728A1/en active Pending
- 2021-08-20 KR KR1020237009717A patent/KR20230054444A/ko active Pending
- 2021-08-20 CN CN202180051106.2A patent/CN115942933A/zh active Pending
- 2021-08-20 HR HRP20241621TT patent/HRP20241621T1/hr unknown
- 2021-08-20 LT LTEPPCT/EP2021/073133T patent/LT4199922T/lt unknown
- 2021-08-20 US US18/040,508 patent/US20230321053A1/en active Pending
- 2021-08-20 WO PCT/EP2021/073133 patent/WO2022038261A1/en not_active Ceased
- 2021-08-20 BR BR112023002778A patent/BR112023002778A2/pt unknown
- 2021-08-20 PT PT217659085T patent/PT4199922T/pt unknown
- 2021-08-20 EP EP21765908.5A patent/EP4199922B1/en active Active
- 2021-08-20 ES ES21765908T patent/ES3001104T3/es active Active
- 2021-08-20 JP JP2023512647A patent/JP7794807B2/ja active Active
- 2021-08-20 SI SI202130242T patent/SI4199922T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230321053A1 (en) | 2023-10-12 |
| EP3957308A1 (en) | 2022-02-23 |
| RS66263B1 (sr) | 2024-12-31 |
| JP2023538419A (ja) | 2023-09-07 |
| EP4199922B1 (en) | 2024-09-25 |
| DK4199922T3 (da) | 2024-11-25 |
| SI4199922T1 (sl) | 2025-03-31 |
| HRP20241621T1 (hr) | 2025-01-31 |
| KR20230054444A (ko) | 2023-04-24 |
| PT4199922T (pt) | 2024-12-18 |
| BR112023002778A2 (pt) | 2023-03-14 |
| LT4199922T (lt) | 2025-01-10 |
| AU2021327728A1 (en) | 2023-03-09 |
| JP7794807B2 (ja) | 2026-01-06 |
| FI4199922T3 (fi) | 2024-12-05 |
| HUE069338T2 (hu) | 2025-02-28 |
| WO2022038261A1 (en) | 2022-02-24 |
| EP4199922A1 (en) | 2023-06-28 |
| MX2023002156A (es) | 2023-03-01 |
| ES3001104T3 (es) | 2025-03-04 |
| CN115942933A (zh) | 2023-04-07 |
| PL4199922T3 (pl) | 2025-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2645368T3 (es) | Terapias para mejorar la función pulmonar | |
| US10577414B2 (en) | Use of reslizumab to treat moderate to severe eosinophilic asthma | |
| Ohta et al. | Japanese guideline for adult asthma | |
| EP4199922B1 (en) | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases | |
| CN116419746A (zh) | 右旋普拉克索用于治疗中度至重度哮喘的用途 | |
| US20220380451A1 (en) | Biopharmaceutical compositions and methods for pediatric patients | |
| CN116033900A (zh) | 治疗冠状病毒暴露所致疾病的方法 | |
| HK40091313B (en) | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases | |
| HK40091313A (en) | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases | |
| US20230242652A1 (en) | Treatments for atopic dermatitis | |
| EA048711B1 (ru) | (1r,3s)-3-((5-циано-4-фенилтиазол-2-ил)карбамоил)циклопентан-1-карбоновая кислота и ее производные для применения в лечении заболеваний дыхательных путей | |
| TW202237078A (zh) | 使用德弗米司特(devimistat)治療肉瘤之治療方法及組合物 | |
| Szefler | Asthma: the new advances | |
| TW202539683A (zh) | 透過投予（ｒ）－２［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧雜環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈治療中度至重度氣喘 | |
| US20250205206A1 (en) | Use of dexpramipexole for the treatment of inadequately controlled moderate to severe asthma | |
| US20220054509A1 (en) | Methods of treatment for disease from coronavirus exposure | |
| HK40090654A (zh) | 右旋普拉克索用於治疗中度至重度哮喘的用途 | |
| CN119546306A (zh) | 施用贝舒地尔以治疗慢性移植物抗宿主病的方法 | |
| Shanthala | Study of Bronchial Asthma in Pregnancy | |
| HK1188603B (en) | Therapies for improving pulmonary function | |
| HK1188603A (en) | Therapies for improving pulmonary function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240816 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240816 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250716 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250716 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - SMALL Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250815 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250815 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250924 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250924 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250924 |